As the unofficial winner of the COVID-19 vaccine race (along with partner Pfizer), BioNTech can be considered the No. 1 biotech stock. But the German biotech company is not resting on its laurels: It’s looking to expand its footprint in the U.S., which includes the acquisition of a technology which helps the body’s immune system find and destroy cancer cells. For more, CLICK HERE.
How The “No. 1 Biotech Stock” Is Expanding Its Footprint In The U.S.
- by RobH